Schizophrenia

Adjunctive pimavanserin significantly improved outcomes among patients with predominant negative symptoms of schizophrenia, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.

An antipsychotic with a novel mechanism of action appeared effective and safe among hospitalized patients with schizophrenia, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.

Aristada Initio and Invega Sustenna appeared well tolerated and effective for initiating in-hospital schizophrenia treatment and continuing outpatient treatment, according to a study published in Journal of Clinical Psychiatry.

A combination of olanzapine and samidorphan was well tolerated and not associated with new safety risks compared with olanzapine alone, according to data presented during the Virtual 2020 Schizophrenia International Research Society Congress.

Ketamine appeared associated with psychosis-like symptoms among healthy individuals, according to results of a systematic review and meta-analysis published in JAMA Network Open.

The Mental Health America organization has designated each May as Mental Health Awareness Month.

Researchers have uncovered several prenatal and perinatal factors associated with later psychosis onset, according to results of a systematic review and meta-analysis published in The Lancet Psychiatry.

Patients with schizophrenia and alcohol use disorder experienced a worse illness course than those with only schizophrenia, according to results of a post hoc analysis published in Journal of Clinical Psychiatry.

Clinicians should frequently monitor metabolic traits during early stages of antipsychotic treatment because of rapid and substantial changes that can occur, according to results of a randomized, open-label, pharmacologic trial published in Journal of Clinical Psychiatry.

A combination of olanzapine and samidorphan was not superior to olanzapine alone in the time to first event of exacerbation of disease symptoms in patients with schizophrenia and alcohol use disorder, according to results of a phase 2, randomized clinical trial published in Journal of Clinical Psychiatry.